SecBot SecBot
8-K ·Filed Jul 24, 2026

OTLK

Outlook Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001104659-26-086685
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a binary catalyst removal event, the stock should re-rate to reflect commercial-stage valuation. Monitor first-quarter launch metrics (prescriber adoption, reimbursement coverage, initial sales) and any competitive response from existing anti-VEGF players (Eylea, Vabysmo, off-label Avastin). The 12-year BPCIA exclusivity is a key moat if sustained.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.07
T+0 close · Jul 24, 2026 · via day close
Latest settled
−53.71%
T+60 · $0.4930
Vs SPY
−57.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $1.07entry
  2. T+1 · 4mo ago −15.12%α −15.36% · $0.9040
  3. T+5 · 4mo ago −8.30%α −9.37% · $0.9766
  4. T+20 · 3mo ago −42.82%α −46.12% · $0.6090
  5. T+60 · 28d ago −53.71%α −57.41% · $0.4930
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics announced FDA approval of LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved ophthalmic formulation of bevacizumab. The company expects 12 years of BPCIA exclusivity and is launching into the ~$8.5B U.S. retina market. This is a transformative, binary-clearance event for a pre-revenue biotech, removing the primary regulatory overhang and enabling commercial revenue generation.

Key Facts

  • FDA approved LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration
  • First and only FDA-approved ophthalmic formulation of bevacizumab in the U.S.
  • Company anticipates 12 years of Reference Product Exclusivity under the BPCIA
  • U.S. anti-VEGF retina market estimated at approximately $8.5 billion annually
  • Commercial launch is now being executed; product expected to be available before year-end 2026
  • Already has EU and UK marketing authorization; commercial launch underway in Germany, Austria, and the UK

Financial Impact

Approval unlocks entry into the ~$8.5B U.S. anti-VEGF retina market; no revenue figures from the filing to quantify initial sales expectations.

revenue

Risk Factors

  • Commercial execution risk, launch may underperform if physician adoption is slower than expected
  • Reimbursement and pricing pressure in the large wet AMD market
  • Competition from established branded anti-VEGF therapies (Eylea, Vabysmo) and continued off-label use of repackaged IV bevacizumab
  • Dependence on successful U.S. commercial infrastructure build-out

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-086685
Document: tm2621316d1_8k.htm0001104659-26-086685
Document: 0001104659-26-086685-index-headers.html0001104659-26-086685
Document: 0001104659-26-086685-index.html0001104659-26-086685
Document: 0001104659-26-086685.txt0001104659-26-086685

Track record

37 reports on OTLK

Performance horizon

13 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Viewing Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026